Medical Affairs and Emerging Therapies Summit
#MAET2024
November 13-15, 2024
Register Apply to Speak
About Medical Affairs and Emerging Therapies Summit 2024
November 13-15, Las Vegas, NV

Biogate Scientific Center is honored to invite you to the Medical Affairs and Emerging Therapies Summit that brings together healthcare professionals and industry experts to discuss the latest trends and insights related to the development and commercialization of emerging therapies, foster collaboration and networking among industry experts and stakeholders, and help drive innovation in the field of medical affairs.

Apply to Speak

At A Glance
DATE:
November 13-15, 2024
LOCATION:
Las Vegas
NV
CONTACT:
Sachin Sravan
sachin@bsc.events
Reasons to Attend
By attending #MAET2024, you can gain new knowledge, create memorable experiences, and hear about the latest breakthroughs in Medical Affairs and Emerging Therapies while connecting with colleagues and top professionals from around the globe. Here are a few reasons why #MAET2024 is an unparalleled event in the field:
STAY UP TO DATE
MAET2024 will provide an opportunity to learn about the most recent breakthroughs in Medical Affairs and Emerging Therapies research and treatment.
NETWORKING
MAET2024 will bring together researchers, clinicians, and industry leaders, providing an excellent opportunity to connect with others in the field, share ideas and collaborate on new research projects.
LEARN FROM LEADERS
MAET2024 will feature presentations and talks by thought leaders in Medical Affairs and Emerging Therapies, providing attendees with the opportunity to gain insights into the latest research and clinical practices.
EXPAND KNOWLEDGE
Attending MAET2024 will provide a chance to expand your knowledge of Medical Affairs and Emerging Therapies, including emerging technologies and innovative treatment approaches.

WHO SHOULD ATTEND?

Medical Affairs and Medical Science Liaisons
Executives in Pharmaceutical and Biotech Companies
Stakeholders in the Healthcare Industry
Regulatory Affairs Professionals
Medical Directors
Medical Writers
Researchers
Clinical Trial Managers
Healthcare Consultants
Patient Advocacy Groups
Session Tracks
Medical Affairs and Emerging Therapies Summit - 2024
Track 1
Regulatory Landscape for Emerging Therapies
This track explores the regulatory considerations and challenges associated with emerging therapies, including gene therapy, cell therapy, immunotherapy, and personalized medicine. It will cover topics such as accelerated approvals, real-world evidence, and post-marketing surveillance
Track 2
Medical Affairs Strategy and Planning
This track addresses the strategic role of medical affairs in the development and launch of emerging therapies. It will cover topics such as medical affairs leadership, stakeholder engagement, evidence generation plans, and the integration of medical affairs with other functions.
Track 3
Clinical Development and Medical Affairs Collaboration
This track focuses on the collaboration between medical affairs and clinical development teams in the context of emerging therapies. It will cover topics such as investigator-initiated trials, data dissemination, medical monitoring, and medical affairs support during clinical trials.
Track 4
Patient-Centric Medical Affairs
This track explores the importance of patient-centricity in medical affairs activities related to emerging therapies. It will cover topics such as patient engagement strategies, patient advocacy, patient support programs, and the use of real-world data to improve patient outcomes.
Track 5
Health Economics and Outcomes Research (HEOR) in Emerging Therapies
This track addresses the role of health economics and outcomes research in supporting the value proposition of emerging therapies. It will cover topics such as health technology assessments, economic modeling, patient-reported outcomes, and market access considerations.
Track 6
Medical Affairs in Rare Diseases and Orphan Drugs
This track focuses on the unique challenges and opportunities faced by medical affairs professionals in the field of rare diseases and orphan drugs. It will cover topics such as patient identification and enrollment, natural history studies, expanded access programs, and engagement with patient advocacy groups.
Track 7
Medical Affairs in Precision Medicine
his track explores the role of medical affairs in the implementation of precision medicine approaches, including biomarker-driven therapies and companion diagnostics. It will cover topics such as diagnostic testing strategies, evidence requirements, and collaborations with diagnostic companies.
Track 8
Emerging Technologies
Understanding the impact of emerging technologies such as artificial intelligence, digital health, and genomics on the development and commercialization of emerging therapies.
Who Can Speak?
Medical Affairs Professionals
Medical Affairs professionals who have experience in emerging therapies can share their insights and best practices in areas such as strategy development, stakeholder engagement, and scientific communications.
Industry Experts
Industry experts with a background in emerging therapies can offer unique perspectives on new and innovative treatments and therapies, as well as provide insights into the future of the industry.
Thought Leaders
Thought leaders who are highly respected within the medical affairs community can share their expertise and insights on key topics related to emerging therapies and medical affairs.
Academics and Researchers
Academics and researchers who have conducted studies or published research in areas related to emerging therapies can provide valuable insights into the latest research and developments in the field.
Regulatory Experts
Regulatory experts who have experience in emerging therapies can provide insights into the regulatory landscape, including the challenges and opportunities related to navigating the regulatory environment.
Key Insights
Medical Affairs and Emerging Therapies Summit - 2024
Emerging therapies and their potential impact on patient outcomes:
Attendees will gain insights into the scientific basis and mechanisms of action of emerging therapies, and how they have the potential to improve patient outcomes.
Clinical trial design and execution for emerging therapies:
Strategies for designing and executing clinical trials for emerging therapies will be discussed, including patient selection, trial endpoints, and trial design considerations.
Regulatory and market access considerations for emerging therapies:
Attendees will gain insights into regulatory and market access considerations for emerging therapies, including the development of clinical trial protocols that meet regulatory requirements, expedited approval pathways, and reimbursement strategies.
Medical communications for emerging therapies:
Strategies for developing medical communications plans for emerging therapies will be discussed, including developing key messages and scientific data, engaging with key opinion leaders, and leveraging digital platforms.
Patient engagement and advocacy for emerging therapies:
Attendees will gain insights into patient perspectives on emerging therapies and strategies for engaging with patient advocacy groups to ensure that patient needs are adequately addressed.
Scientific publications for emerging therapies:
Strategies for developing scientific publications that effectively communicate the clinical data and scientific evidence supporting emerging therapies will be discussed.
Healthcare professional education for emerging therapies:
Strategies for developing educational programs that provide healthcare professionals with the knowledge and skills needed to effectively diagnose and treat patients with emerging therapies will be discussed.
Commercialization and launch of emerging therapies:
Considerations for the commercialization and launch of emerging therapies, including pricing and reimbursement strategies, marketing and promotional efforts, and key opinion leader engagement will be discussed.
BSC Speakers
Stephen L. Hoffman
Chief Executive and Scientific Officer, Sanaria Inc., USA
Robert O. Dillman
Chief Medical Officer, AIVITA Biomedical, Inc., USA
Kevin P Killeen
Chief Scientific Officer, Matrivax, USA
Christy A. Comeaux
Medical Lead, Clinical Development, Janssen Vaccines & Prevention B.V., Netherlands
Trudy Morrison
Professor, University of Massachusetts Chan Medical School, USA
Alexandre Le Vert
Executive Chairman, Chief Executive Officer & Co-founder, Osivax, France
Mic McGoldrick
Associate Director Global CMC Policy, Merck & Co., Inc. on behalf of IFPMA, USA
Mark J. Newman
Chief Scientific Officer, GeoVax, USA
Joseph Joyce
Distinguished Scientist, Vaccine Process Research & Development (VPRD), Merck, USA
Jerald Sadoff
Senior Advisor, Clinical Development, Janssen Vaccines and Prevention, Leiden, Netherlands
Mark Emalfarb
President & CEO, Dyadic International, USA
Feng Xuan
Co-founder, President & CTO, Spear Bio, USA
Martin Moore
Founder & Chief Scientific Officer, Meissa Vaccines, USA
Lynda Tussey
Chief Development Officer, Vaxess Technologies, USA
James Z Deng
Associate Principal Scientist, Vaccine Analytical R&D, Merck, USA
Kun Zhou
Project Lead, GeneLeap Biotech, USA
Why Sponsor?
Sponsoring Medical Affairs and Emerging Therapies Summit will be a valuable opportunity for companies and organizations involved in the development and commercialization of emerging therapies. Here are a few reasons why:
Increase visibility and brand awareness:
Sponsoring MAET2023 can increase the visibility of your organization among a targeted audience of medical affairs professionals, key opinion leaders, and decision-makers.
Build relationships with key stakeholders:
Sponsoring MAET2023 provides an opportunity to connect with key stakeholders in the industry, including healthcare providers, patient advocacy groups, regulatory authorities, and others, and to build relationships that will lead to new collaborations and partnerships.
Showcase expertise and thought leadership:
Sponsoring MAET2023 provides a platform to showcase your expertise and thought leadership in the development and commercialization of emerging therapies, and to position your company as a leader in the field.
Launch new products and services:
Sponsoring MAET2023 will provide an opportunity to launch new products or services related to emerging therapies, and to generate interest and excitement among a targeted audience.
Keep up to date on industry trends and insights:
Sponsoring MAET2023 provides an opportunity to stay up-to-date on the latest trends and insights related to the development and commercialization of emerging therapies, and to learn from experts and peers in the field.

Registration Opens April 15, 2024

Medical Affairs and Emerging Therapies Summit

ACADEMIC
$450
INDUSTRY
$750
STUDENT
$150
VIRTUAL
$99

Cancellation Policy

All cancellations must be sent by email at sachin@bsc.events
Cancellations received up and including June 18, 2023: full refund less a $150 towards the administrative fee.
Cancellations received between June 19 until September 21, 2024: 50% will be refunded.
Cancellations received from September 22, 2024: no refund will be made.

Group Registration
If you would like to register a team of 3 or more,
please contact: sachin@bsc.events for your discount coupon code before registering

BSC Attendees